German HTA Body Says Well Done On Immuno-Oncology, But Where Are Dementia Breakthroughs?
Executive Summary
Germany’s health technology appraisal institute, IQWiG, says that oncology drugs take up more of its time than treatments for any other conditions. And while it welcomes advances in immuno-oncology, it wants to see breakthroughs in other disease areas too.
You may also be interested in...
What will become of the German antidiabetics market?
Yet another company – this time Novo Nordisk – has decided that it wouldn't be good business to sell its antidiabetic in Germany following a rocky ride through the AMNOG benefit assessment and pricing negotiations. While companies are worried about the future of treatments for chronic diseases in Germany, prescribers and health insurers are more sanguine and believe that German patients are not yet missing out on important innovations in the market.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.